NEWS

Home News

New Team member

Expanding Our Scientific Capacity: Welcoming Onat A. to MUB Medical

By Yasar Shaikh in 2025 Posted September 5, 2025

We are pleased to announce that Onat Akbulut, has joined MUB Medical Solutions as part of our growing scientific and technical development team.

Onat is currently pursuing his PhD in Cell & Tissue Engineering and holds a degree in Metallurgical and Materials Engineering. His academic work is anchored in Bioengineering and the Cell & Tissue Engineering, where he focuses on the interface between biological tissues and engineered materials.

At MUB, Onat will play a central role in the design and development of pre-clinical studies related to our Sutrips technology. His expertise in tissue healing, material-tissue interaction, and biological response analysis brings important depth to our product development team. He will also contribute to material evaluation and help ensure that our choices align with both clinical performance goals and biological compatibility standards.

With Onat joining forces with Natale Rolim and Sara Zulfiqar, we are building a dedicated and interdisciplinary foundation for moving Sutrips forward through the final stages of product development, pre-clinical validation, and regulatory preparation.

“With Onat on board, we gain not only deep academic expertise but also a scientific mindset that complements our regulatory and clinical development goals. His contribution will be important as we finalize our pre-clinical planning and ensure the biological strength of our technology,” says Yasar Shaikh, CEO of MUB Medical Solutions.

We look forward to the next steps in our journey and are proud to have Onat as part of the team.

READ MORE

Building the Foundation: Two Key Regulatory Profiles Join MUB Medical Solutions

By Yasar Shaikh in 2025 Posted August 29, 2025

As MUB Medical Solutions continues the development of Sutrips, we are strengthening our team with the core competencies needed to bring the technology through the next critical phases — including material development and validation, regulatory alignment, and clinical readiness.

We are therefore pleased to welcome Dr. Natale Rolim and Sara Zulfiqar to the MUB team. Their expertise will be instrumental in laying the groundwork for the product’s completion and in supporting the regulatory and documentation processes required to prepare Sutrips for future clinical testing and market introduction.

Dr. Natale Rolim – Regulatory Affairs Specialist

With a scientific background and experience in health innovation, Dr. Natale Rolim will lead the development of our regulatory strategy. Her work will focus on aligning Sutrips with both FDA and EUMDR requirements, and ensuring that all processes are structured, compliant, and scalable. Natale’s insight will be central in preparing the product for the demanding documentation and traceability standards required in medical device development.

Sara Zulfiqar – Biomedical Innovation & Quality Systems

With a Master’s in Biomedical Innovation & Development from Georgia Institute of Technology, USA, Sara brings practical experience in building regulatory systems from the ground up. At MUB, she will contribute to:

  • Shaping the 510(k) pathway for FDA clearance
  • Designing IEC 62366-1 compliant Human Factors Engineering (HFE) studies
  • Authoring and implementing a QMS in line with ISO 13485:2016 tailored to Class II medical devices

“The recruitment of Natale and Sara marks an important step in building the internal capacity needed to finalize the development of Sutrips. Their expertise will enable us to qualify materials, strengthen documentation processes, and ensure regulatory readiness for both the EU and US markets. We are still in an active development phase, and these hires represent the foundation we need to complete the work ahead,” says Yasar Shaikh, CEO of MUB Medical Solutions.

At MUB Medical, we remain committed to developing innovative wound closure solutions that are safe, simple, and clinically meaningful — and we are proud to now have Natale and Sara onboard to support that mission.

 

READ MORE

MUB Medical Secures U.S. Patent for Sutrips

By Yasar Shaikh in 2025 Posted July 31, 2025

MUB Medical Secures U.S. Patent for Sutrips

MUB Medical is proud to announce that Sutrips has officially been granted a U.S. patent.

This achievement marks a major milestone in our journey and further strengthens our robust global IP portfolio, which already includes patents in Europe, China, Eurasia, Russia, Australia, Mexico, Brazil, Indonesia, India, and South Africa – and now also the United States.

Sutrips is more than just a medical device; it is a versatile acute wound closure platform designed to simplify suturing across a wide range of clinical scenarios, from acute care to minimally invasive and robotic surgery.

The U.S. patent represents not only legal protection but also validation of our mission: to make suturing simpler, safer, and more efficient, thereby enabling healthcare professionals to dedicate more time to what matters most – their patients.

With this milestone, MUB Medical is even better positioned to scale globally, enter new markets, and continue driving innovation in acute wound closure.

Together, we are shaping the future of acute wound closure.

READ MORE
EMWA - MUB Medical

MUB Medical Joins EWMA

By Ubbat Ocak in 2023 Posted September 25, 2023

MUB Medical joins EWMA – European Wound Management Association

We are honored to announce that MUB Medical Solutions has become a proud member of the European Wound Management Association (EWMA), a distinguished not-for-profit organization dedicated to advancing wound care excellence across Europe and beyond.

EWMA, established in 1991 as a registered charity in the UK, serves as a unifying force, connecting national wound management organizations, individuals, and groups passionate about wound care. At the core of EWMA’s mission lies the commitment to promote interdisciplinary and cost-effective wound care of the highest quality.

As an active member of EWMA, MUB Medical Solutions is poised to leverage this invaluable network to further our mission of making wound closure accessible, affordable, and efficient for all. We eagerly anticipate the opportunity to collaborate with experts within the EWMA community, sharing insights and expertise about our innovative solution, Sutrips.

Through our partnership with EWMA, we aim to amplify awareness about Sutrips and its transformative impact on wound closure. Together, we can drive progress, raise standards in wound management, and contribute to a healthier and more informed healthcare landscape.

We express our heartfelt gratitude to EWMA for this collaboration and look forward to a fruitful and impactful journey ahead.

To learn more about EWMA and its mission, please visit the EWMA website.

To learn more about Sutrips, please visit MUB Medical and follow our LinkedIn page.

READ MORE

Introducing Sutrips

By Ubbat Ocak in 2023 Posted May 29, 2023

Introducing Sutrips-
Wound Closure with Adjustable Tension

We are thrilled to unveil the much-anticipated product introduction video for Sutrips, our game-changing suture tool that is set to transform the field of wound closure.

Sutrips: Precision in Every Stitch

Sutrips is not just another ordinary suture tool. It’s a breakthrough innovation that empowers healthcare professionals to achieve exceptional wound closure results. With Sutrips, we have harnessed the power of adjustable tension, allowing for a new level of precision and control in each stitch.

Advanced Technology, Optimal Healing

By providing the ability to apply different tension to each stitch, Sutrips offers unparalleled versatility and customization. This means healthcare professionals can adapt the tension to suit the specific needs of each wound, ensuring optimal healing outcomes. Whether it’s a deep laceration, a delicate incision, or any other wound type, Sutrips enables precise tension application for superior results.

Innovation at Its Finest

Sutrips represents a significant leap forward in wound closure technology. It eliminates the limitations of traditional suture tools by integrating adjustable tension capabilities into a user-friendly, all-in-one device. This not only streamlines the suturing process but also enhances patient comfort and minimizes complications.

Empowering Healthcare Professionals, Elevating Patient Care

We are proud to equip healthcare professionals with the tools they need to deliver the highest standard of care. Sutrips empowers them to achieve remarkable results, reduce procedural time, and optimize the healing journey for their patients. By harnessing the power of adjustable tension, Sutrips paves the way for advancements in wound closure techniques and improved patient outcomes.

Join Us on the Journey

We invite you to watch our product introduction video to witness the groundbreaking capabilities of Sutrips. Together, let’s revolutionize wound closure and make a lasting impact on the healthcare industry. Like, comment, and share this post to spread the word and join us on this exciting journey!

Explore also about Patent Issued in Indonesia.

READ MORE

Patent Issued in Indonesia

By Ubbat Ocak in 2023 Posted March 6, 2023

 

Securing Patent in Indonesia

We are thrilled to announce that MUB Medical Solutions has successfully secured a patent for our innovative wound closure solution, Sutrips, in Indonesia. With a population of over 270 million, Indonesia represents a significant and promising market for our product.

The patent grant in Indonesia further strengthens our position and allows us, along with our esteemed partners, to enforce protection rights for the sales and distribution of Sutrips in this important market. This milestone achievement underscores our commitment to delivering cutting-edge solutions and protecting our intellectual property.

“We are delighted to receive the patent for Sutrips in Indonesia,” said Ubbat Ocak, Founder of MUB Medical Solutions. “This achievement solidifies our market presence in the region and enables us to bring our innovative wound closure technology to healthcare professionals and patients in Indonesia.”

The Indonesian market holds immense potential due to its large population and growing healthcare needs. The patent provides us with a strong foundation to establish partnerships, expand market reach, and cater to the demands of healthcare providers seeking advanced wound closure solutions.

“We recognize the significance of the Indonesian market and the opportunities it presents,” stated Yasar Shaikh, CEO of MUB Medical Solutions. “Securing the patent for Sutrips in Indonesia empowers us to deliver superior quality products while upholding our commitment to intellectual property rights and ensuring the best outcomes for healthcare professionals and patients alike.”

MUB Medical Solutions remains dedicated to innovation, research, and development to continuously improve the wound closure process. The patent grant in Indonesia is a testament to our relentless pursuit of excellence and our determination to provide state-of-the-art solutions to healthcare providers globally.

As we continue to expand our market presence in Indonesia and other strategic regions, we invite healthcare professionals, distributors, and potential partners to join us on this exciting journey. Together, we can make a significant impact on the wound closure industry and enhance patient care.

Stay connected with MUB Medical Solutions through our website and social media channels for the latest updates on our products, partnerships, and advancements in the field of wound closure.

Great news: MUB Medical joins Aleap.

READ MORE

MUB Medical Joins Aleap

By Ubbat Ocak in 2022 Posted November 1, 2022

Aleap for health startups

MUB Medical Joins Aleap in Oslo to Accelerate Commercialization

We are thrilled to announce that MUB Medical Solutions has joined Aleap, the largest incubator for health startups in the Nordics. This exciting partnership marks a significant milestone in our journey to revolutionize wound closure with our innovative product, Sutrips.

Aleap’s unique incubator model is designed to support ambitious entrepreneurs in building successful growth companies. With access to world-class competence, a vast network of industry experts, and funding opportunities, we are confident that our membership with Aleap will propel us forward on our mission.

Ubbat Ocak and Yasar Shaikh, CEOs of MUB Medical, express their enthusiasm about this collaboration. They firmly believe that joining Aleap will provide them with invaluable knowledge and connections that will expedite the process of bringing Sutrips to the market.

By becoming a part of Aleap, we are aligning ourselves with a vibrant ecosystem of like-minded innovators and industry leaders. This collaboration will undoubtedly foster an environment of collaboration, learning, and growth, enabling us to make a tangible impact in the field of wound closure.

We extend our heartfelt gratitude to Aleap for their belief in our vision and for providing us with this remarkable opportunity. We are excited to embark on this journey together and look forward to leveraging the resources and support offered by Aleap to bring Sutrips to healthcare providers and patients worldwide.

Stay tuned for more updates on our progress as we continue to push the boundaries of innovation and transform the landscape of wound closure.

Do you know that  MUB Medical Visited Center for Surgical Science at Zealand University Hospital last week?

READ MORE

Visiting Center For Surgical Science

By Ubbat Ocak in 2022 Posted October 26, 2022

 

MUB Medical Visits Center for Surgical Science at Zealand University Hospital

Last week, the team at MUB Medical had the privilege of visiting the prestigious Center for Surgical Science at Zealand University Hospital in Denmark. The visit proved to be an enlightening experience, as we engaged in fruitful discussions about our patented suturing technology and its potential to revolutionize the suturing process.

During our conversation, we received valuable feedback on our flagship product, Sutrips, which has the potential to significantly enhance the efficiency of suturing procedures. However, the benefits of our technology didn’t stop there. We were thrilled to discover that it holds promise for various other types of operations as well.

Building upon this positive interaction, we are excited to announce that we will be initiating collaborative work with the Center for Surgical Science to explore the development of a potential spin-off product based on our core patent. This collaboration opens up new avenues for innovation and reinforces our commitment to advancing medical technologies.

At MUB Medical, we understand the importance of engaging with end-users and gathering industry insights. It is through these interactions that we can refine our products to better meet the needs of healthcare professionals and patients alike. We are grateful for the opportunity to collaborate with esteemed institutions like the Center for Surgical Science and look forward to the possibilities that lie ahead.

Stay tuned for more updates as we continue our journey of transforming the field of wound closure and improving healthcare outcomes.

Explore Patent Issued in Australia.

READ MORE

Proof of Concept Completed

By Ubbat Ocak in 2022 Posted September 25, 2022

Proof of Concept Completed

We are thrilled to share a momentous achievement in our ongoing journey to transform wound closure with Sutrips.

In our recent independent proof-of-concept study, Sutrips was tested against the conventional interrupted suture technique.

The results speak volumes, and we couldn’t be more excited to reveal our progress!

This milestone takes us one step closer to realizing our mission: making wound closure universally accessible, affordable, and efficient.

For those eager to delve deeper into the proof-of-concept findings, we invite you to explore the full report, available for download. Please click here.

Stay tuned as we continue to pioneer innovation in wound closure for a healthier world.

READ MORE

MUB Medical Secures Funding for Proof-of-Concept

By Ubbat Ocak in 2022 Posted August 4, 2022

MUB Medical Secures Funding for Proof-of-Concept

We are thrilled to announce that MUB Medical has received financing from Innovation Norway to further advance the proof-of-concept stage for Sutrips. This marks the third time that Innovation Norway has supported us financially, and we are incredibly grateful for their ongoing trust and belief in our vision.

With the backing of Innovation Norway, we are now focused on preparing for Sutrips’ global market introduction. We will actively engage with key industry players to explore potential collaborations for the successful launch of Sutrips.

It’s an exhilarating time for us, and we invite you to follow us on LinkedIn for more exciting updates. Stay tuned as we share the remarkable results of our proof-of-concept, which we have recently completed.

Thank you for your unwavering support and enthusiasm as we work towards revolutionizing wound care with Sutrips – a simple Scandinavian solution for a complex global problem.

READ MORE